Orbimed Advisors Llc decreased Assembly Biosciences Inc (ASMB) stake by 39.8% reported in 2018Q1 SEC filing. Orbimed Advisors Llc sold 476,860 shares as Assembly Biosciences Inc (ASMB)’s stock declined 24.71%. The Orbimed Advisors Llc holds 721,166 shares with $35.44 million value, down from 1.20M last quarter. Assembly Biosciences Inc now has $965.06 million valuation. The stock increased 1.80% or $0.83 during the last trading session, reaching $46.96. About 153,542 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 70.43% since June 17, 2017 and is uptrending. It has outperformed by 57.86% the S&P500. Some Historical ASMB News: ; 12/04/2018 – ASSEMBLY BIOSCIENCES INC ASMB.O SAYS GENERALLY SAFE AND WELL TOLERATED; PLANNING UNDERWAY FOR PHASE 2A STUDIES BEGINNING SUMMER 2018; 12/04/2018 – Assembly Biosciences: Data Show Excellent Potency, Dose Response Across Patient Cohorts as Well as a Favorable Safety Profil; 12/03/2018 – Assembly Biosciences Appoints Helen S. Kim to Board of Directors; 20/04/2018 – DJ Assembly Biosciences Inc, Inst Holders, 1Q 2018 (ASMB); 28/03/2018 – Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL); 12/03/2018 – Assembly Biosciences Appoints Graham Cooper as Chief Financial Officer and Operating Chief; 28/03/2018 – Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Con; 10/04/2018 – Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in; 07/05/2018 – Assembly Biosciences 1Q Loss/Shr 80c; 10/04/2018 – Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL
Par Pacific Holdings, Inc. (PARR) formed triangle with $16.27 target or 7.00% below today’s $17.49 share price. Par Pacific Holdings, Inc. (PARR) has $802.47M valuation. The stock decreased 2.56% or $0.46 during the last trading session, reaching $17.49. About 510,367 shares traded or 124.15% up from the average. Par Pacific Holdings, Inc. (NYSE:PARR) has risen 5.39% since June 17, 2017 and is uptrending. It has underperformed by 7.18% the S&P500. Some Historical PARR News: ; 08/05/2018 – PAR PACIFIC 1Q ADJ EPS 18C, EST. $0.0; 05/03/2018 PAR PACIFIC 4Q REV. $663.1M, EST. $590.0M; 21/04/2018 – DJ Par Pacific Holdings Inc, Inst Holders, 1Q 2018 (PARR); 05/03/2018 – Par Pacific Holdings 4Q Rev $663.1M; 08/05/2018 – Par Pacific Holdings 1Q EPS 33c; 23/03/2018 – Par Pacific Holdings, Inc. Successfully Closes Acquisition Of 33 Cenex(R) Zip Trip Retail Locations In Washington And Idaho; 05/03/2018 – PAR PACIFIC HOLDINGS INC – QTRLY REVENUES $663.1 MLN VS $563.1 MLN; 08/05/2018 – Par Pacific Holdings 1Q Adj EPS 18c; 05/03/2018 – Par Pacific Holdings 4Q Adj EPS 53c; 08/05/2018 – PAR PACIFIC 1Q REV. $765.4M
Analysts await Par Pacific Holdings, Inc. (NYSE:PARR) to report earnings on August, 6. They expect $0.25 EPS, up 4.17% or $0.01 from last year’s $0.24 per share. PARR’s profit will be $11.47M for 17.49 P/E if the $0.25 EPS becomes a reality. After $0.18 actual EPS reported by Par Pacific Holdings, Inc. for the previous quarter, Wall Street now forecasts 38.89% EPS growth.
More notable recent Assembly Biosciences, Inc. (NASDAQ:ASMB) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on June 15, 2018, also Nasdaq.com with their article: “Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018” published on June 13, 2018, Nasdaq.com published: “Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on June 08, 2018. More interesting news about Assembly Biosciences, Inc. (NASDAQ:ASMB) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant …” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “36 Biggest Movers From Friday” with publication date: June 11, 2018.
Among 5 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Assembly Biosciences had 7 analyst reports since November 8, 2017 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, May 8 by FBR Capital. FBR Capital maintained the stock with “Hold” rating in Friday, March 9 report. The firm has “Neutral” rating by Chardan Capital Markets given on Friday, April 13.